NeuroPace warns Q3 revenue uncertainty due to COVID-19 Delta variant procedure delays

NeuroPace Inc

Procedure volumes impacted in Q3 due to scheduling delays from COVID-19 Delta variant.
Management believes delays will create uncertainty around revenue for second half of 2021.
Company to participate in three healthcare conferences: Wells Fargo, Morgan Stanley, Baird.

item 7.01

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-21-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.